Recommendations for management of antiphospholipid syndrome in China
10.3760/cma.j.cn112138-20211222-00907
- VernacularTitle:抗磷脂综合征诊疗规范
- Author:
Jiuliang ZHAO
1
;
Haili SHEN
;
Kexia CHAI
;
Chengde YANG
;
Yan ZHAO
Author Information
1. 中国医学科学院 北京协和医学院 北京协和医院风湿免疫科 国家皮肤与免疫疾病临床医学研究中心 疑难重症及罕见病国家重点实验室 风湿免疫病学教育部重点实验室，北京 100730
- Keywords:
Antiphospholipid syndrome;
Pregnancy morbidity;
Thrombotic events;
Classification;
Treatment
- From:
Chinese Journal of Internal Medicine
2022;61(9):1000-1007
- CountryChina
- Language:Chinese
-
Abstract:
Antiphospholipid syndrome (APS) is a systemic autoimmune disorder with vascular, obstetric, and hematological manifestations associated with thrombotic and inflammatory mechanisms orchestrated by antiphospholipid (aPLs) antibodies. Current clinical practice in APS is highly variable duo to lack of high quality of evidence. Here, Chinese Rheumatology Association developed recommendations for management of APS in China. The recommendations cover the early diagnosis, disease evaluation, thrombotic risk assessment, and treatment.
